Peter A. Kaufman, MD

Articles by Peter A. Kaufman, MD

An expert on breast cancer presenting slides from a study

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

December 20th 2022

Peter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

ByPeter A. Kaufman, MD

February 7th 2013

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

Latest Updated Articles

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer
December 20th 2022
Dr. Kaufman on Eribulin/ Capecitabine Side Effects
February 7th 2013

Peter A. Kaufman, MD

Articles by Peter A. Kaufman, MD

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

Latest Updated Articles

Trending on OncLive

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

The OncFive: Top Oncology Articles for the Week of 5/31

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer